medigraphic.com
ISSN 0016-3813 (Impreso)

2006, Número 2

<< Anterior Siguiente >>

Gac Med Mex 2006; 142 (2)


Tratamiento de pacientes con linfomas no Hodgkin asociados a SIDA: experiencia del Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Uriarte-Duque J, Hernández-Rivera G

Idioma: Español
Referencias bibliográficas: 33
Paginas: 99-102
Archivo PDF: 454.57 Kb.


RESUMEN

Antecedentes: La supervivencia de los pacientes con linfomas no Hodgkin asociados al Síndrome de Inmunodeficiencia Adquirida (SIDA) ha mejorado con el uso de antirretrovirales y de quimioterapia menos tóxica.
Material y métodos: El objetivo del estudio fue mostrar los resultados del tratamiento de los pacientes con linfomas no Hodgkin y SIDA. Se estudiaron nueve pacientes de manera retrospectiva. Se analizó la supervivencia global y libre de enfermedad mediante curvas de Kaplan-Meier; además de sus características generales.
Resultados: El tratamiento recibido fue a base de etopósido, prednisona, vincristina, doxorrubicina y ciclofosfamida (DA-EPOCH). Los pacientes tuvieron supervivencia global de 18 meses, una supervivencia libre de enfermedad de 13 meses, una mediana de seguimiento de 16 meses con respuestas completas en ocho de nueve pacientes.
Conclusiones: Se observó una adecuada repuesta a tratamiento en este grupo de enfermos reflejada en una mayor supervivencia global.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000;27:390-401.

  2. Centers for disease control. Revision of the case definition of acquired immunodeficiency syndrome for national reporting-United States. Ann Intern Med 1985;103:402-403.

  3. Levine AM, Meyer PR, et al. Development of B-cell lymphoma in homosexual men: clinical and immunologic finding. Ann Intern Med 1984;100:7-13.

  4. Ziegler JL, Beckstead JA. Non-Hodgkin’s lymphoma in 90 homosexual men. N Engl J Med 1984;31:565-570.

  5. Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992;80:8-20.

  6. Kalter SP, Riggs SA, et al. Aggressive non-Hodgkin’s lymphoma in immunocompromised homosexual males. Blood 1985;66:655-659.

  7. Knowles DM, Chamulak GA. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;108:744-753.

  8. Kaplan LD, Abrams DI. AIDS associated non-Hodgkin’s lymphoma in san Francisco. JAMA 1989;261(5):719-724.

  9. Grabar S, Le Moing V, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000;133:401-403.

  10. Kaplan LD, Straus DJ. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997;336:1641-1648.

  11. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000;27:442-453.

  12. Sparano JA, Wiemik PH. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgastrim in patients with human immunodeficiency virus-associated non-Hodgkin’s lymphoma. J Clin Oncol 1996;14:3026-3035.

  13. Ratner L, Lee J. Chemotherapy for human immunodeficiency virusassociated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19:2171-2178.

  14. N’ Galy B, Bertozzi S. Obstacles to the optimal management of HIV infection/AIDS in Africa. J Acquir Immune Defic Syncir 1990;3:430-437.

  15. B. Borisch, M.Raphael, SH. Swerdlow. Lymphoproliferative diseases associated with primary immune disorders. En: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Jaffe E.S, Harris N.L, Stein H, Vardiman J.W. IARC press: Lyon 2001. p. 257-263.

  16. Rosenberg SA. Validity of the Ann Arbor Staging Classification for the Non- Hodgkin’s Lymphomas. Cancer Treat Rep 1977;61:1023-1027.

  17. Armitage JO, Weisenburger DD. New Approach to classifying non-Hodgkin’s Lymphoma: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795.

  18. World Health Organization. Common toxity criteria (CTC). 30 April 1999. p. 8-10.

  19. Kazunori Ohnishi. Current trends in the management of malignant lymphoma: new WHO classification, guidelines for high-dose therapy with HSCT, and new response criteria. Int J Clin Oncol 2000;5:1-7.

  20. Centers for Disease control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome.MMWR.1987;36(suppl1S)1S-15S.

  21. Alexandra M. Levine, Lasika Seneviratne. Evolving characteristics of AIDS-related lymphoma. Blood 2000;96:4084-4090.

  22. Tulpule A, Sherrod A, Dharmapala et al. Multidrug resistance (MDR-1) expression in aids-related lymphomas Leuk Res 2002;26:121-127.

  23. Richard F. little, Stefania Pittaluga. Highly effective treatment of acquired immunodeficiency syndrome- related lymphoma with dose adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-4659.

  24. Besson C, Goubar A, Gabarre J et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy Blood 2001;98:2339-2344.

  25. Caroline Besson, Aicha Goubar. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-2344.

  26. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy Aids 2001;15:1483-1491.

  27. Ledergerber B, Telenti A, Effer M. Risk of HIV related Kaposi’s sarcoma and non-Hodgkin’s lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J 1999;319:23-24.

  28. Rabkin CS, Testa MA, Fischl MA, et al. Declining incidence of Kaposi’s sarcoma in AIDS clinical trial group (ACTG) trials(abstract S4). J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:A39.

  29. Jacobson LP. Impact of highly effective anti-retroviral therapy on the incidence of malignancies among HIV-infected individual (abstract S5). J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:A39.

  30. Romeu J, Navarro T, Tural C, et al. Effect of HAART on response to therapy and survival in patients with AIDS-related non-Hodgkin’s lymphoma(abstract TuPeB3162). Program and abstracts of the XIII International AIDS; Durban, South Africa 2000:9-14.

  31. Caroline Besson, Aicha Goubar. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy Blood 2001;98:2339-2344.

  32. Centers for Disease control and prevention. Update: AIDS among women-United States,1994.MMWR. 1995;44:81-84.

  33. Hernández-Rivera G, Gómez Roel X, Villasís-Keever. Linfomas nohodgkin asociados a SIDA: 1) evolución de los 20 años de la pandemia.2) experiencia en el INCMNSZ. Rev Invest Clin 2004;56(2):186-192.




2020     |     www.medigraphic.com